GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Total Tax Payable

DNTH (Dianthus Therapeutics) Total Tax Payable : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Total Tax Payable?

Dianthus Therapeutics's Total Tax Payable for the quarter that ended in Sep. 2024 was $0.00 Mil.


Dianthus Therapeutics Total Tax Payable Historical Data

The historical data trend for Dianthus Therapeutics's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Total Tax Payable Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Total Tax Payable
- - -

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Dianthus Therapeutics Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.


Dianthus Therapeutics Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Dianthus Therapeutics Business Description

Traded in Other Exchanges
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.